FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

ASCO Reaches Out to FDA, NIH, CMS

[ Price : $8.95]

The Association for Clinical Oncology tells the new leaders of FDA, NIH, and CMS it looks forward to working with them on behalf o...

Cobenfy Effective as Schizophrenia Adjunct: Trial

[ Price : $8.95]

Bristol Myers Squib says its Cobenfy showed positive results in the Phase 3 ARISE trial as an adjunctive therapy to atypical antip...

Update Drug Labels with Obesity Info: Pitts

[ Price : $8.95]

Former FDA associate commissioner Peter Pitts calls on the agency to revise drug labels with obesity safety and effectiveness info...

Lilly Sues 4 More Weight-Loss Drug Compounders

[ Price : $8.95]

Lilly sues four additional drug compounders for illegally selling copies of its weight loss and diabetes drugs.

Alert Issued on Conavis Novasight Catheters

[ Price : $8.95]

The catheter is part of a system intended for intravascular imaging of coronary arteries.

FDA Seeks Post-Marketing Commitment from Novavax

[ Price : $8.95]

Novavax says its Covid-19 vaccine BLA is being held up while FDA seeks to conclude a post-marketing commitment from the company.

CereVasc Gains Breakthrough Status for eShunt

[ Price : $8.95]

FDA grants CereVasc a breakthrough device designation for its investigational eShunt System and its use in treating communicating ...

ESG NextGen is Live: FDA

[ Price : $8.95]

FDA says its Electronic Submission Gateway Next Generation is live and ready to receive submissions.

Vanda Criticizes FDA on Tradipitant Hearing Delay

[ Price : $8.95]

Vanda Pharmaceuticals criticizes FDA for wrongly claiming that recent staff cuts and a new commissioner causes it to delay a compa...

Akesos Ivonescimab Meets Endpoint in Lung Cancer

[ Price : $8.95]

Akeso says its ivonescimab met the primary endpoint in a pivotal Phase 3 trial for the first-line treatment of advanced squamous n...